Abstract
Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.
| Original language | English |
|---|---|
| Pages (from-to) | 465-474 |
| Number of pages | 10 |
| Journal | CiOS Clinics in Orthopedic Surgery |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2016 Dec 1 |
Fingerprint
Keywords
- Chronic non-cancer pain
- Emotional functioning
- Fentanyl matrix
- Physical functioning
ASJC Scopus subject areas
- Surgery
- Orthopedics and Sports Medicine
Cite this
Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain : Improvement of pain and physical and emotional functions. / Lee, Jaewon; Yoon, Joon Shik; Lee, Jae Hyup; Chung, So Hak; Lee, Kyu Yeol; Kim, Young Yul; Kim, Jong Moon; Kong, Min Ho; Kang, Ung Gu; Park, Ye Soo.
In: CiOS Clinics in Orthopedic Surgery, Vol. 8, No. 4, 01.12.2016, p. 465-474.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain
T2 - Improvement of pain and physical and emotional functions
AU - Lee, Jaewon
AU - Yoon, Joon Shik
AU - Lee, Jae Hyup
AU - Chung, So Hak
AU - Lee, Kyu Yeol
AU - Kim, Young Yul
AU - Kim, Jong Moon
AU - Kong, Min Ho
AU - Kang, Ung Gu
AU - Park, Ye Soo
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.
AB - Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.
KW - Chronic non-cancer pain
KW - Emotional functioning
KW - Fentanyl matrix
KW - Physical functioning
UR - http://www.scopus.com/inward/record.url?scp=84995622163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995622163&partnerID=8YFLogxK
U2 - 10.4055/cios.2016.8.4.465
DO - 10.4055/cios.2016.8.4.465
M3 - Article
C2 - 27904731
AN - SCOPUS:84995622163
VL - 8
SP - 465
EP - 474
JO - Clinics in Orthopedic Surgery
JF - Clinics in Orthopedic Surgery
SN - 2005-291X
IS - 4
ER -